Vistara Bioscience

Vistara Bioscience is developing proteomics tools for drug discovery research in Targeted Protein Degradation (TPD) and other therapeutic modalities. Our TRIFECTA strategy is a combination of ubiquitomics, compound screening, and protein disruption processes for clinical applications in Oncology, Inflammation, and Neurodegeneration disease areas. Recent clinical outcomes in TPD have stressed the sobering reality that TPD solutions are not merely plug-and-play, rather have underscored the need for including more detailed information about the clinical target's proteostasis mechanisms into the TPD solution. Our global ubiquitome scanning technologies identify the similarities and differences between samples, and highlights the contextual information of target protein's proteostasis. These include protein networks, accessory factors, pathway components, and compound-induced changes of proteins which are in close collaboration with proteins of clinical interest. By combining our processes, design tools, and informatics, we design the choicest TPD solutions. The networks serve as biomarker panels to follow along the drug discovery process, and additionally, may suggest combinatorial targets or new ones.